Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745145 · ClinicalTrials.gov registry record · Phase 2
Abituzumab in SSc-ILD
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02745145 is a Phase 2 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 24 participants.
The verdict
NCT02745145, a Phase 2 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the treatment of participants with SSc-ILD who already receive constant doses of mycophenolate.
Interventions
- DRUG Placebo
- DRUG Abituzumab 1500 mg
- DRUG Abituzumab 500 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745145
The ClinicalTrials.gov registry entry for NCT02745145 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02745145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745145 about?
NCT02745145 is a clinical study titled "Abituzumab in SSc-ILD". The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the treatment of participants with SSc-ILD who already receive constant doses o...
What is the current status of trial NCT02745145?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-05-31. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT02745145?
The interventions under investigation include: Placebo (DRUG), Abituzumab 1500 mg (DRUG), Abituzumab 500 mg (DRUG).
Who is sponsoring clinical trial NCT02745145?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.